Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)~  * Stage IIIA or IIIB disease~* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion \> 20 mm by conventional techniques or \> 10 mm by spiral CT scan~* No clinically significant malignant pleural or pericardial effusion (i.e., stage IIIB wet disease)~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Absolute neutrophil count \> 1,500/mm³~* Platelet count \> 100,000/mm³~* Hemoglobin ≥ 8.0 g/dL~* Bilirubin normal~* Alkaline phosphatase (AP), AST, and ALT meeting 1 of the following criteria:~  * AP normal AND AST or ALT ≤ 5 times upper limit of normal (ULN)~ * AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN~ * AP ≤ 5 times ULN AND AST or ALT normal~* Creatinine \< 2.0 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for ≥ 3 months after completion of study treatment~* No New York Heart Association class III-IV heart disease~* No history of serious cardiac disease not adequately controlled~* No documented myocardial infarction within the past 6 months~* No congestive heart failure~* No unstable angina~* No clinically significant arrhythmia~* No history of severe hypersensitivity reaction to drugs formulated with polysorbate 80~* No peripheral neuropathy \> grade 1~* No other malignancy within the past 5 years other than skin cancer~PRIOR CONCURRENT THERAPY:~* More than 3 weeks since prior major surgery~* No prior systemic chemotherapy, thoracic radiotherapy, or surgical resection for NSCLC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).